TICKERNERD
Menu
ASTHASTHHealthcare · Medical Care Facilities

ASTH Stock Forecast: Astrana Health, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$39
+1.66% on the day

The 10 Wall Street analysts covering Astrana Health, Inc. hold a median 12-month price target of $52 — +30.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 65 of 100 as at 22 Aug 2026 — in the upper half.

Market cap
$2.0B
Ticker Nerd rank
65 / 100
Median analyst target
$52
Analysts covering
10
Total return, dividends reinvested
1W
−3.5%
1M
−13.4%
YTD
+58.7%
1Y
+31.4%
From 52W high
−20.9%
From 52W low
+116.9%
$18
$50
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ASTH stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Astrana Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
65 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
92
Momentum
86
Revisions
77
Value
70
Quality
45
Volatility
42
Size
37
Accruals
30
Issuance
24

Growth (92): Sales and profits are climbing, and climbing faster than before.

Issuance (24): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ASTH stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ASTH, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$30$40$50$60$70Oct 25Jan 26Apr 26Jul 26ASTHHigh $65Median $52Low $41

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says10 analysts
9 Buy1 Hold0 Sell
Low $41Median $52High $65

The green dot is the last close — the median target sits +30.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
11 Aug 2026Truist SecuritiesMaintainsBuy$47 → $55
7 Aug 2026BarclaysMaintainsOverweight$50 → $53
14 July 2026BTIGMaintainsBuy—
14 July 2026BTIGMaintainsBuy$50 → $65
14 July 2026TD CowenMaintainsBuy—
14 July 2026TD CowenMaintainsBuy$45 → $50
2 June 2026BTIGReiteratesBuy—
26 May 2026BarclaysUpgradeOverweight—
14 May 2026Truist SecuritiesMaintainsBuy—
12 May 2026TD CowenMaintainsBuy—
11 May 2026BarclaysMaintainsEqual-Weight—
8 May 2026BTIGMaintainsBuy—
8 May 2026NeedhamMaintainsBuy—
15 Apr 2026BairdMaintainsOutperform—
13 Mar 2026Truist SecuritiesMaintainsBuy—
2 Feb 2026BTIGMaintainsBuy—
12 Dec 2025NeedhamInitiatesBuy—
25 Nov 2025JefferiesMaintainsBuy—
24 Nov 2025BarclaysMaintainsEqual-Weight—
10 Nov 2025TD CowenMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ASTH appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ASTH analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+4.1%
Analysts raising
0
Analysts cutting
0
Fundamentals

Astrana Health, Inc. (ASTH) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
48.0×

Cheaper than 15% of US stocks

Price / sales
0.5×

Cheaper than 82% of US stocks

Price / book
2.3×

Cheaper than 42% of US stocks

EV / EBITDA
13.5×

Cheaper than 27% of US stocks

Growth & margins
Revenue growth (YoY)
48.5%

Higher than 86% of US stocks

Earnings growth (YoY)
109.5%

Higher than 85% of US stocks

Gross margin
11.0%

Higher than 11% of US stocks

Operating margin
3.5%

Higher than 52% of US stocks

Net margin
1.1%

Higher than 50% of US stocks

Returns & dividend
Return on equity
6.9%

Higher than 57% of US stocks

Return on assets
3.8%

Higher than 69% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ASTH vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Care Facilities
CompanyMarket capTKN rank
ASTHAstrana Health, Inc.$2.0B
65
SGRYSurgery Partners, Inc.$1.9B
47
SNDASonida Senior Living, Inc.$1.9B
27
MDPediatrix Medical Group, Inc.$2.2B
99
ADUSAddus HomeCare Corp.$2.3B
95
HCSGHealthcare Services Group, Inc.$1.6B
97
AGLAgilon Health, Inc.$1.6B
63

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Astrana Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ASTH news & analysis

Astrana Health: 81% Full-Risk And Profitable

Seeking Alpha · 12 Aug 2026positive

Seeking Alpha rated Astrana Health a buy, noting a 46% discount to peers and highlighting its Care Enablement platform's role in reducing G&A costs and quadrupling third-party revenue year-over-year. The company's organic growth is driven by a shift into full-risk capitation with projected revenue-per-member expansion.

Why it matters — ASTH watchers would be interested in the company's margin improvement through its Care Enablement platform, the growing shift to full-risk capitation, and its trading discount relative to peers.

Astrana Health, Inc. (ASTH) Q2 2026 Earnings Call Transcript

Seeking Alpha · 7 Aug 2026neutral

Astrana Health, Inc. held its Q2 2026 earnings call, and a transcript of the call was published on Seeking Alpha. The transcript covers the company's second-quarter 2026 financial results and management discussion.

Why it matters — A transcript of the earnings call gives ASTH watchers access to management's commentary on the company's latest quarterly performance.

Astrana Health, Inc. (ASTH) Q2 Earnings Top Estimates

Zacks Investment Research · 7 Aug 2026positive

Astrana Health, Inc. (ASTH) reported Q2 earnings of $0.40 per share, surpassing the Zacks Consensus Estimate of $0.31 per share, and up from $0.19 per share in the same quarter last year.

Why it matters — The earnings beat and year-over-year growth signal stronger-than-expected financial performance for Astrana Health in its latest quarter.

Astrana Health Q2 Earnings Call Highlights

MarketBeat · 6 Aug 2026positive

Astrana Health reported second-quarter 2026 revenue of $973 million, up 49% from a year earlier, while adjusted EBITDA rose 43% to $69 million. Adjusted diluted earnings per share reached a record $0.80, up 45% year over year, driven by growth in value-based care arrangements, medical-cost management, Prospect Health acquisition synergies and operating leverage.

Why it matters — The company's double-digit year-over-year growth across revenue, EBITDA and record EPS highlights the financial impact of its value-based care expansion and Prospect Health acquisition, making it a notable update for ASTH watchers.

Astrana Health, Inc. Reports Second Quarter 2026 Results

PRNewsWire · 6 Aug 2026neutral

Astrana Health, Inc. reported its second quarter 2026 results. The company will host a conference call on Thursday, August 6, 2026, at 2:30 p.m. PT / 5:30 p.m. ET to discuss the results.

Why it matters — ASTH watchers would want to know about the company's latest quarterly earnings release and the upcoming conference call where management is scheduled to discuss its Q2 2026 performance.

FAQ

Frequently asked questions about ASTH stock

What is the ASTH stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Astrana Health, Inc. have a median 12-month price target of $52, with estimates ranging from $41 to $65. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ASTH stock a buy right now?

Of the 10 analysts covering Astrana Health, Inc., 9 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Astrana Health, Inc. 65 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ASTH?

As at 22 Aug 2026, Astrana Health, Inc. ranks 65 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (92 of 100).

Will ASTH stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +30.8% from the last close, and Ticker Nerd's factor model ranks Astrana Health, Inc. 65 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ASTH stock forecast for 2030?

No analyst covering Astrana Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ASTH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $41 to $65 over the next 12 months.

How has ASTH stock performed over the past year?

Astrana Health, Inc. returned +31.4% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Astrana Health, Inc. do?

Astrana Health Inc. is a physician-centric, technology-powered, risk-bearing healthcare management company operating in the United States.

What is the latest news on ASTH?

The most recent item we track (Seeking Alpha, 12 Aug 2026): "Astrana Health: 81% Full-Risk And Profitable". Seeking Alpha rated Astrana Health a buy, noting a 46% discount to peers and highlighting its Care Enablement platform's role in reducing G&A costs and quadrupling third-party revenue year-over-year. The company's organic growth is driven by a shift into full-risk capitation with projected revenue-per-member expansion.

Company

About Astrana Health, Inc.

Astrana Health Inc. is a physician-centric, technology-powered, risk-bearing healthcare management company operating in the United States. It provides medical care services through three key segments: Care Partners, Care Delivery, and Care Enablement, leveraging a proprietary population health management and healthcare delivery platform. This integrated, value-based healthcare model empowers providers in its network to deliver high-quality, cost-effective care to patients. The company offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative inpatient sites, physician groups, and health plans. Astrana Health Inc. functions as an integrated healthcare delivery platform, encompassing primary care, multi-specialty care, immediate care, radiology, and laboratory services. Founded in 1985 and headquartered in Alhambra, California, it plays a significant role in the value-based care sector by aligning physician incentives with patient outcomes and operational efficiency.

CEO Mr. Brandon K. Sim M.S. · 3,000 employees · United States · https://www.astranahealth.com